April 30, 2026

PERSONAL AND CONFIDENTIAL

Elisabet de los Pinos

Re: Separation Agreement

Dear Ms. de los Pinos:

This letter confirms the termination of your employment with Aura Biosciences, Inc. (the “Company”), effective April 30, 2026 (the “Separation Date”).

If you enter into, do not revoke, and comply with this separation agreement (the “Release Agreement”), the Company will provide you with the opportunity to receive the severance benefits outlined in this Release Agreement, which you agree shall supersede the severance benefits set forth in your Offer of

Employment dated January 22, 2010 (the “Offer Letter”), the Employment Agreement dated January 1, 2015, as amended on October 13, 2017 (the “Employment Agreement”), and the Company’s Executive Severance Plan (including your Participation Agreement thereunder, the “Severance Plan”). You and the Company agree that all notice provisions in Section 9 of the Employment Agreement have been fully satisfied.

With those understandings and regardless of whether you enter into the Release Agreement, the following bulleted terms and conditions apply in connection with the ending of your employment:

The remainder of this letter proposes the Release Agreement between you and the Company. You and the Company agree as follows:

Your employment with the Company shall terminate, effective as of the Separation Date. Following the Separation Date, you will immediately transition into an advisory role in which you provide certain advisory and transitional services to the Company, subject to the terms of a Consulting Agreement (the “Consulting Agreement”), attached hereto as Exhibit A.

Provided you enter into, do not revoke and comply with this Release Agreement, the Company shall provide you with the below “Severance Benefits.”

During the course of your employment, you were awarded a total of 839,049 Restricted Stock Units (the “Award”) and stock options to purchase 2,544,748 shares of the Company’s common stock (the “Option”), in each case under the Company’s 2009 Amended and Restated Stock Option and Restricted Stock Plan, 2018 Equity Incentive Plan and 2021 Stock Option and Incentive Plan and associated restricted stock unit award agreements and stock option agreements (collectively, the “Equity Documents”). As of the Separation Date, 415,374 Restricted Stock Units will have previously vested (all of which have been issued to you as shares) and 1,956,231 shares of the Option vested. As of the Separation Date, 52,512 of such vested Options were previously exercised by you. The remaining 423,675 Restricted Stock Units of the Award and 573,919 shares of the Option shall be unvested as of the Separation Date and shall become null and void as of such date, unless you enter into the Consulting Agreement under which your equity will continue to vest (as described below and in the Consulting Agreement). The vested and unexercised equity as of the Separation Date, along with any other equity that may vest during the Consulting Period (as described in the Consulting Agreement) is collectively referred to herein as the “Vested Equity”.

The Vested Equity shall continue to be subject to the terms and conditions of the Equity Documents, provided that you agree, effective as of the Separation Date, you shall have the opportunity to sell up to 300,000 shares of your Vested Equity during a two-week open trading window following the consummation of the next public offering or a private placement of the Company’s equity securities that occurs on or after the Separation Date, subject to (x) your not being in possession of material non-public information at the time of such sale and (y) your compliance with the Company’s Trading Policy (as defined below). In accordance with the Consulting Agreement, you are also eligible for continued vesting during the Consulting Period (as defined in the Consulting Agreement).

For the avoidance of doubt, as provided in the Equity Documents, except in the event of disability, death or Cause, the post-service relationship exercise period for any vested equity shall not begin until after your service relationship with the Company has ended (i.e. after the Consulting Period ends), and your continued compliance with the terms and conditions of this Release Agreement, the Company shall extend the period during which you may exercise your vested shares underlying the Option (such shares, the “Extended Options”) until the earlier of (i) June 30, 2028; or (ii) the end of the original option term. You expressly consent to such extension of the post-termination exercise period of the Extended Options and acknowledge that, to the extent such options were intended to be “incentive stock options” described in Section 422 of Internal Revenue Code, this extension may cause them to instead be subject to taxation as non-qualified stock options. For the avoidance of doubt, during the Consulting Period and thereafter as specified in the Company’s Amended and Restated Insider Trading Policy (the “Trading Policy”), you shall at all times comply with the Trading Policy.

In consideration for, among other terms, the opportunity to continue your service relationship with the Company pursuant to the Consulting Agreement and to receive the Severance Benefits, each of which you acknowledge you would otherwise not be entitled to, you voluntarily release and forever discharge the Company and its affiliated and related entities, their respective predecessors, successors and assigns, its and their respective employee benefit plans and fiduciaries of such plans, and the current and former officers, directors, managers, members, shareholders, employees, attorneys, accountants and agents of each of the foregoing in their official and personal capacities (collectively referred to as the “Releasees”)

generally from all claims, demands, debts, damages and liabilities of every name and nature, known or unknown (“Claims”) that, as of the date when you sign this Release Agreement, you have, ever had, now claim to have or ever claimed to have had against any or all of the Releasees. This release includes, without limitation, all Claims:

provided, however, that this release shall not affect your rights under this Release Agreement or the Consulting Agreement or any rights that cannot be released under applicable law.

You acknowledge and represent that, except as expressly provided in this Release Agreement, the Company has paid or provided all salary, wages, bonuses, accrued vacation/paid time off, premiums, leaves, severance, reimbursable expenses, commissions, stock, stock options, equity awards, vesting, and any and all other benefits and compensation due to you.

Subject to Section 7 of this Release Agreement, you agree not to accept damages of any nature, other equitable or legal remedies for your own benefit or attorney’s fees or costs from any of the Releasees with respect to any Claim released by this Release Agreement. As a material inducement to the Company to enter into this Release Agreement, you represent that you have not assigned any Claim to any third party.

You agree to return to the Company by the Separation Date all credit cards and any documents (including electronic documents as well as hard copies) containing confidential or proprietary information concerning the Company, its business or its business relationships . You further agree to return to the Company by the Outside Date (as defined in the Consulting Agreement) any computer equipment, keys and access cards. You also commit to deleting and finally purging any duplicates of files or documents that may contain Company information from any computer or other device that remains your property

after the Outside Date. In the event that you discover that you continue to retain any such property, you shall return it to the Company immediately. For the avoidance of doubt, throughout the term of the Consulting Agreement, you shall be granted access to the Company premises and access to the Company parking lot as reasonably necessary for purposes of performing the services under the Consulting Agreement. Following the Separation Date, you shall be permitted and provided reasonable time to download your business contacts from your Company e-mail account, provided any such downloads do not contain confidential or proprietary information belonging to the Company. Upon reasonable request by you, the Company will forward any personal e-mails sent to your Company email account to your personal e-mail address.

Subject to Section 7 of this Release Agreement, you agree that you will not directly or indirectly, make any statement, public or private, oral or written, to any person that disparages, either professionally or personally, the Company, and each of them, as well as its and their past and present directors, officers, partners, agents, attorneys, insurers, stockholders, representatives, assigns, successors, and employees, in each case, of whom you have knowledge. You represent that during the period since this Release Agreement was proposed to you, you have not made any such disparaging statements.

The Company agrees to direct its directors and C-Suite executives not to make disparaging statements, either professionally or personally, about you.

Nothing contained in this Release Agreement, any other agreement with the Company (including without limitation the Ongoing Obligations), or any Company policy limits your ability, with or without notice to the Company, to: (i) file a charge or complaint with any federal, state or local governmental agency or commission (a “Government Agency”), including without limitation, the Equal Employment Opportunity Commission, the National Labor Relations Board or the Securities and Exchange Commission (the “SEC”); (ii) communicate with any Government Agency or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including by providing non-privileged documents or information; (iii) discuss or disclose information about unlawful acts in the workplace, such as harassment or discrimination or any other conduct that you have reason to believe is unlawful; or (iv) testify truthfully in a legal proceeding. Any such communications and disclosures must not violate applicable law and the information disclosed must not have been obtained through a communication that was subject to the attorney-client privilege (unless disclosure of that information would otherwise be permitted consistent with such privilege or applicable law). If a Government Agency or any other third party pursues any claim on your behalf, you waive any right to monetary or other individualized relief (either individually or as part of any collective or class action), but the Company will not limit any right you may have to receive an award pursuant to the whistleblower provisions of any applicable law or regulation for providing information to the SEC or any other Government Agency.

For the avoidance of doubt, pursuant to the federal Defend Trade Secrets Act of 2016, you shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that (a) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.

This Release Agreement is not intended to provide for any deferral of compensation subject to Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), and, to the maximum extent permitted by applicable law, amounts payable to you pursuant to Section 2 shall be made in reliance upon Treasury Regulation Section 1.409A-1(b)(9) (with respect to separation pay plans) or Treasury Regulation Section 1.409A-1(b)(4) (with respect to short-term deferrals). To the extent applicable, this Release Agreement shall be interpreted in accordance with Code Section 409A and Department of Treasury regulations and other interpretive guidance issued thereunder consistent with the foregoing intention. Each series of installment payments made under this Release Agreement is hereby designated as a series of “separate payments” within the meaning of Section 409A of the Code. Notwithstanding anything herein to the contrary, to the extent any payments to you hereunder constitute “non-qualified deferred compensation” subject to Section 409A of the Code or are intended to be exempt from Section 409A of the Code pursuant to Treasury Regulation Section 1.409A-1(b)(9), then, to the extent required by Section 409A of the Code or to satisfy such exception, no amount shall be payable pursuant to such sections unless your termination of employment constitutes a “separation from service” with the Company (as such term is defined in Treasury Regulation Section 1.409A-1(h) and any successor provision thereto) (a “Separation from Service”). If you are a “specified employee” (as defined in Section 409A of the Code), as determined by the Company in accordance with Section 409A of the Code, on the date of your Separation from Service, to the extent that the payments or benefits under this Release Agreement constitute “non-qualified deferred compensation” subject to Section 409A of the Code and the delayed payment or distribution of all or any portion of such amounts to which you are entitled under this Release Agreement is required in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code, then such portion deferred pursuant to this Section shall be paid or distributed to you in a lump sum on the earlier of (A) the date that is six (6) months following your Separation from Service, (B) the date of your death or (C) the earliest date as is permitted under Section 409A of the Code. Any remaining payments due under this Release Agreement shall be paid as otherwise provided herein. Further, in the event that the amounts payable under Section 2 constitute “non-qualified deferred compensation” subject to Section 409A of the Code and the timing of the delivery of this Release Agreement could cause such amounts to be paid in one or another taxable year, then, notwithstanding the payment timing set forth in such sections, such amounts shall not be payable until the later of (A) the payment date specified in such section or (B) the first business day of the taxable year following your Separation from Service. Any reimbursements or in-kind benefits payable under this Release Agreement shall be made in accordance with Treasury Regulation Section 1.409A-3(i)(1)(iv) and shall be paid on or before the last day of your taxable year following the taxable year in which you incurred the expenses. The reimbursements or in-kind benefits provided under this Release Agreement during any taxable year of yours will not affect such amounts provided in any other taxable year of yours, and your right to reimbursement for such amounts shall not be subject to liquidation or exchange for any other benefit. The Company makes no representation or warranty and shall have no liability to you or any other person if any provisions of this Release Agreement are determined to constitute deferred compensation subject to Section 409A but do not satisfy an exemption from, or the conditions of, Section 409A.

[Signature Page Follows]

Please indicate your agreement to the terms of this Release Agreement by signing and returning to the undersigned the original or a PDF copy of this letter within the time period set forth above.

Very truly yours,

Aura Biosciences, Inc.

By:

/s/ Dave Johnson
Name: Dave Johnson
Title: Chairman of the Board of Directors

You are advised to consult with an attorney before signing this Release Agreement. This is a legal document. Your signature will commit you to its terms. By signing below, you acknowledge that you have carefully read and fully understand all of the provisions of this Release Agreement and that you are knowingly and voluntarily entering into this Release Agreement.